Clinical trial NCT05200169: Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects
Official title: An Open-Label, Non-Randomised, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Healthy Volunteers
Lead sponsor: AB Science
Sponsor class: INDUSTRY
First posted: 2022-01-20
Enrollment: 4
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: An open label, non-randomized, single-dose, single-period study
Primary purpose: TREATMENT

Brief summary: To assess the mass balance recovery after a single oral dose of 14C-AB1010

Detailed description: The objective is to characterize the distribution, metabolism and elimination of AB1010 in humans through the sampling of blood, urine, and faeces. This is accomplished through the administration of 14C-AB1010 oral solution with a therapeutic relevant dose of AB1010 as a single oral dose. There was no control group and no blinding as the objective was to assess the mass balance of masitinib after a single oral intake. There was only one group of healthy male volunteers.

Eligibility criteria: Inclusion Criteria Included:

* Healthy Male as determined by a physician, based on a medical evaluation including medical history, physical examination, clinical laboratory tests and 12-lead ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the Sponsor Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
* Male between 18 and 65 years old inclusive, at the time of signing the informed consent.
* Body mass index of 18.0 to 32.0 kg/m2, inclusive at screening
* Body weight between 60 and 90 kg
* Normal blood pressure and heart rate or, if abnormal, considered not clinically significant by the principal Investigator or sub-investigator.
* Neutrophils count should be within normal range or deemed as not clinically significant by the PI
* Must have regular bowel movements (ie, average stool production of ≥1 and ≤3 stools per day)

Exclusion Criteria Included:

* Any clinically significant cardio vascular diseases such as but not limited to the common reported below:

  * History or presence or suspect of Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery bypass graft surgery or stent procedure;
  * History or presence or suspect of Angina Pectoris;
  * History or presence or suspect, heart failure;
  * Abnormal vital signs
  * Clinically significant abnormal Blood Pressure according to investigator's opinion
  * Abnormal resting ECG according investigator's opinion.
* Clinically significant, abnormal medical history, physical findings, ECG, or laboratory values at the screening visit that could interfere with the objectives of the study or the safety of the volunteer.
* A history of clinically significant acute illness (resolved within 4 weeks of screening), or history of significant cardiac arrhythmias or unexplained syncope or presence of cardiovascular, gastrointestinal, renal, hepatic, neurologic, haematologic, endocrine, oncologic, pulmonary, immunologic, dermatologic or psychiatric disease or any other condition which, in the opinion of the Principal Investigator (PI), would jeopardize the safety of the subject or impact the validity of the study results.
* Subject has an uncontrolled intercurrent illness (i.e., active infection) or fever (oral temperature \> 38 degrees Celsius) at screening.
* Clinically significant history of or current seizure disorder or history of syncope, unexplained loss of consciousness or clinically significant history of Central Nervous System (CNS) disorders
* Failure to satisfy the investigator of fitness to participate for any other reason

Primary outcomes:
measure: Radioactivity recovery
timeFrame: 168 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
city: Nottingham
country: United Kingdom
facility: Quotient Sciences
Study officials:
affiliation: Quotient Clinical Ltd
name: Nand Singh, MD
role: PRINCIPAL_INVESTIGATOR
References: